Premium
Tolerance to nicotinic acid flushing
Author(s) -
Stern Ralph H,
Spence J David,
Freeman David J,
Parbtani Anwar
Publication year - 1991
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1991.104
Subject(s) - nicotinic agonist , metabolite , prostaglandin , clinical pharmacology , chemistry , pharmacology , mediator , plasma concentration , endocrinology , medicine , biochemistry , receptor
The mechanism of tolerance to nicotinic acid flushing was determined in subjects during a 5‐day course of treatment. Objective measures of skin blood flow were used to confirm the development of tolerance. Plasma levels of nicotinic acid showed marked intraindividual variability but were not decreased with the development of tolerance. However plasma levels of 9‐α 11‐β prostaglandin F 2 , a stable metabolite of prostaglandin D 2 , became undetectable in most subjects with the development of tolerance. Thus tolerance is not associated with decreased levels of nicotinic acid or development of tolerance to the prostaglandin mediator, but with decreased levels of the mediator. Clinical Pharmacology and Therapeutics (1991) 50 , 66–70; doi: 10.1038/clpt.1991.104